Eurocine Vaccines publishes CEO interview

CEO Hans Arwidsson discussed the vaccine portfolio, the progress with the chlamydia vaccine candidate, and the future plans for the business in an interview conducted in collaboration with Finwire.

See the interview via the following link (in Swedish):
Eurocine Vaccines´ CEO interview

Eurocine Vaccines´ portfolio strategy and development were discussed together with CEO Hans Arwidsson. The progress in the development of the chlamydia vaccine candidate and the work of expanding the portfolio of vaccine candidates are some of the points addressed in the interview.

“It is a perfect example of when to prevent rather than treat. That is where the vaccine comes in” says Dr. Hans Arwidsson, CEO of Eurocine Vaccines and refers to chlamydia infection, which may be asymptomatic and yet cause complications.

Hans Arwidsson, Ph.D., MBA

CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com

+46 70 634 0171

Eurocine Vaccines is a development company in the highly intense vaccine area, bridging the gap between innovation and market.

Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. These candidates are later licensed to partners for commercialization.

The company is in the possession of its own technology platform, Endocine™, which has been tested in four extensive clinical studies with over 400 subjects.

Listed at Spotlight Stock Market, XSAT, Eurocine Vaccines, EUCI, today operates at the heart of the bio-scientific cluster of Karolinska Institutet, Solna, Sweden and has attracted several internationally merited vaccine specialists to its board.